Language: 简体中文 English
Su Ryon Shin
Su Ryon Shin, Ph.D.
Work E-Mail:,
Work Phone:  617-835-1164
Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02139, USA.

Dr. Shin is one of the innovative and productive young faculties in regenerative medicine and biomedical engineering, with a growing international reputation for her accomplishments. Dr. Shin fully committed to address this major challenge head-on by using an interdisciplinary approach at the interface between tissue engineering, biomaterials, nanomaterials, biosensor, bioactuator, bioprinting, and organ-on-a-chip. Dr. Shin’s research focuses on developing micro- and nanoscale technologies to control and monitor cellular behavior with particular emphasis in developing microscale biomaterials and engineering systems for biomedical applications. She has been developing multifunctional cardiac scaffolds and 3D biohybrid actuator using biocompatible hydrogel for both therapeutic purposes and in vitro studies. Her team currently focuses on developing bioprinting technology to control cellular behavior, as well as regulating cell alignment within engineered systems. Also, Dr. Shin has been developing and testing of integrated organs-on-chip systems with built-in biosensors. Dr. Shin is one of the most productive and prolific young innovators in the country. During my research period at the Brigham, Dr. Shin has been extremely prolific in my work, which has resulted in several funded grants by DOD-Advanced Regenerative Manufacturing Institute, Air Force Office of Sponsored Research, Qatar University, and Toyota Company. In addition, she has published over 87 papers in peer-reviewed journals such as PNAS, Advanced Materials, ACS Nano, Angewandte Chemie, etc. Her H index, which is a measure of scientific productivity, is already at 35. In just a few years she has been cited over 3,690 times. Dr. Shin is a 2015 and 2018 recipient of a BWH Stepping Strong Innovator Award.

Selected Awards and Honors: 
Best thesis award, Hanyang University (2009); Stepping Strong Innovator Award, Brigham and Women's Hospital (2015); Microgrant Award, Brigham Research Institute Stepping Strong (2016); Innovator Award, Brigham and Women's Hospital (2018); Best Project Award, UTIB International R&D Brokerage Event, Turkey (2018)

Microengineered hydrogels for tissue fabrication and organ-on-a-chip application

    Tissue engineering holds great promise as an alternative therapy by creating func-tional tissue constructs that can reestablish the structure and function of injured tissue. However, a major challenge in tissue engineering is recapitulating the in vitro, three-dimensional (3D) hierarchical microarchitecture comprised of multiple cell types and the extracellular matrix (ECM) components of native tissues, along with achievement of continuous function and viability of engineered tissues after implantation. Specifi-cally, survival of implanted cell-laden scaffolds is fully dependent on the oxygenation derived by its connection to blood circulation of the host body. The physiological pro-cess of angiogenesis is time-consuming, which results in the failure of clinically sized implants due to starvation-induced cell death, especially in thick and large constructs. Therefore, the incorporation of functional vasculature is important for maintaining thick and large complex tissue constructs, particularly in cardiac and skeletal muscle tissues that require highly vascularized networks to support the large metabolically ac-tivity in muscle cells. To address these challenges, 3D bioprinting is emerging as a powerful technique for the development of highly organized and complex 3D con-structs. Its use offers a versatile means to optimize tissue constructs by providing flex-ibility in modulating the composition, structure, and architecture of the scaffolds. To achieve in vivo-like biological functions in 3D tissue constructs, ECM-based bio-materials are required to mimic biological and physical properties that will enhance the resulting tissue function. We envision that developing hybrid bioinks that are func-tionalized by growth factors or nanomaterials could be useful in creating more custom-ized and biomimetic 3D-printed tissue constructs for various biomedical applications.
     In addition, the engineered 3D tissue constructs can be used for toxicity assays based on organs-on-a-chip platforms, which have become increasingly important for drug discovery. The organs-on-a-chip system allows for the testing of cytotoxic ef-fects of pharmaceutical compounds and nanomaterials on physiologically relevant hu-man tissue models prior to moving forward with expensive animal testing or clinical trials. To successfully establish organs-on-a-chip platforms, it is critically important to continuously monitor the dynamic behaviors of human organ models interacting with drugs in situ for an extended period of time. We introduce a fully integrated and au-tomated platform of microfluidic, label-free, resuable, biosensing technology com-bined with a human organ-on-a-chip system, which jointly allows for long-term and accurate measurements of the concentrations of the biomarkers secreted by both tis-sues in response to a panel of drugs. When combined with an automated microfluidic system, the electrochemical biosensing chip will demonstrate a built-in capability for regenerating its sensor surface, allowing for continual kinetic studies over extended periods of time. We believe that this novel platform technology may be further ex-tended to a wide variety of applications in academia and pharmaceutics for personal-ized screenings of drug toxicity, efficacy, and pharmacokinetics in the future.

  • DAYS
Key Dates
   Deadline for Submission of Abstract:
  October 31, 2018
   Notification of abstract acceptance:
   November 15, 2018